Time-dependent population PK models of single-agent atezolizumab in patients with cancer.

Mathilde MarchandRong ZhangPhyllis ChanValerie QuarmbyMarcus BallingerNitzan SternheimBenjamin WuJin Y JinRené Bruno

Published in: Cancer chemotherapy and pharmacology (2021)

The overall impact of covariates on atezolizumab CL did not warrant any change in atezolizumab dosing recommendations. The results support the hypothesis that variation in atezolizumab CL over time is associated with patients' disease status, as shown with other checkpoint inhibitors.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
dna damage
prognostic factors
peritoneal dialysis
cell cycle
cell proliferation
clinical practice
patient reported outcomes
oxidative stress